Topical imiquimod therapy for lentigo maligna

Annals of Plastic Surgery

Volumn 61, Issue 4, 2008, Pages 419-424

  Mahoney, Mary Helen ^a   Joseph, Mariamma G ^b   Temple, Claire ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c NONE   (Canada)

Author keywords

Imiquimod; Lentigo maligna; Melanoma; Topical therapy

Indexed keywords

IMIQUIMOD; PSEUDOMONIC ACID; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CREAM; CRUSTING; DRUG DOSE SEQUENCE; DRUG RESPONSE; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HERPES SIMPLEX; HISTOLOGY; HUMAN; HYPOPIGMENTATION; INFECTION; MALE; MALIGNANT LENTIGO; MORNING DOSAGE; PAIN; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; TUMOR BIOPSY; CASE REPORT; FACE TUMOR; MIDDLE AGED; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; FACIAL NEOPLASMS; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MALE; MIDDLE AGED; SKIN NEOPLASMS;

EID: 55249112069     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31816714c8     Document Type: Article

References (44)

1. Flotte TJ, Mihm MC Jr. Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Hum Pathol. 1999;30:533-536.
2. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987;116:303-310.
3. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992. Am J Dermatopathol. 1993;15:34-43; discussion 46-51.
4. Cohen LM, McCall MW, Hodge SJ, et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections. Cancer. 1994;73: 2964-2970.
5. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg. 1998;24:673-677.
6. Snow SN, Mohs FE, Oriba HA, et al. Cutaneous malignant melanoma treated by Mohs surgery. Review of the treatment results of 179 cases from the Mohs Melanoma Registry. Dermatol Surg. 1997;23:1055-1060.
7. Nagi C, O'Grady TC, Izadpanah A. Mohs micrographically controlled surgery and the treatment of malignant melanoma. Semin Oncol. 2002; 29:336-340.
8. Zalla MJ, Lim KK, Dicaudo DJ, et al. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26:771-84.
9. Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994;31:79-85.
10. Dhawan SS, Wolf DJ, Rabinovitz HS, et al. Lentigo maligna. The use of rush permanent sections in therapy. Arch Dermatol. 1990;126: 928-930.
11. Stonecipher MR, Leshin B, Patrick J, et al. Management of lentigo maligna and lentigo maligna melanoma with paraffin-embedded tangential sections: utility of immunoperoxidase staining and supplemental vertical sections. J Am Acad Dermatol. 1993;29:589-594.
12. Clayton BD, Leshin B, Hitchcock MG, et al. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg. 2000;26:671-678.
13. Bub JL, Berg D, Slee A, et al. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004;140:552-558.
14. Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure. J Am Acad Dermatol. 1997;37:758-764.
15. Anderson KW, Baker SR, Lowe L, et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg. 2001;3:202-206.
16. Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94:287-292.
17. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol. 2002;147:1-6.
18. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789-794.
19. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43:S6-S11..
20. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg. 2004;8:338-352.
21. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-1007.
22. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138:1498-1502.
23. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-845.
24. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003;139:943-944.
25. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol. 2003;139:944-945.
26. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003;139:945-947.
27. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg. 2004;30:1543-1545.
28. Michalopoulos P, Yawalkar N, Bronnimann M, et al. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151:903-906.
29. Kamin A, Eigentler TK, Radny P, et al. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol. 2005;52(2 Suppl 1):51-52.
30. Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol. 2004;50: 792-796.
31. Ray CM, Kluk M, Grin CM, et al. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol. 2005;44:428-434.
32. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149(suppl 66): 66-70.
33. Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151: 485-488.
34. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immuno-therapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15-21.
35. Elder D. Lever's Histopathology of the Skin. 8th ed. Philadelphia: Lippincott-Raven; 1997.
36. Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol. 2005;91:120-125.
37. Palmer KJ, Harries M, Gore ME, et al. Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol. 2000; 119:412-418.
38. Cornejo P, Vanaclocha F, Polimon I, et al. Intralesional interferon treatment of lentigo maligna. Arch Dermatol. 2000;136:428-430.
39. Turner ML, Moshell AN, Corbett DW, et al. Clearing of melanoma in situ with intralesional interferon alfa in a patient with xeroderma pigmentosum. Arch Dermatol. 1994;130:1491-1494.
40. Steinmann A, Funk JO, Schuler G, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000;43:555-556.
41. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205:135-138.
42. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003;139:273-276.
43. Wolf IH, Cerroni L, Kodama K, et al. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141:510-514.
44. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141.